| Premier Podiatry | |
|
405 Woodlawn Rd, Long Grove, IA 52756-8745 | |
| (832) 425-7457 | |
| (563) 424-7234 |
| Full Name | Premier Podiatry |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 405 Woodlawn Rd, Long Grove, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720445281 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 0705 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Premier Podiatry Po Box 2671, Davenport, IA 52809-2671 Ph: (832) 425-7457 | Premier Podiatry 405 Woodlawn Rd, Long Grove, IA 52756-8745 Ph: (832) 425-7457 |
News Archive
In a clinical trial involving 18,924 patients from 57 countries who had suffered a recent heart attack or threatened heart attack, researchers at the University of Colorado Anschutz Medical Campus and fellow scientists around the world have found that the cholesterol-lowering drug alirocumab reduced the chance of having additional heart problems or stroke.
Although syphilis is one of the oldest known diseases, most health professionals do not have access to the tests necessary to reliably diagnose it in its earliest and most infectious stage. A recent survey of infectious diseases specialists regarding the diagnosis and treatment of syphilis appears in the November 15, 2009 issue of Clinical Infectious Diseases, now available online.
Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009.
Hospitalized premature infants are exposed to unsafe levels of a chemical found in numerous medical products used to treat them, raising questions about whether critically ill newborns may be adversely affected by equipment designed to help save their lives.
Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.
› Verified 7 days ago
Dr. Jim Paul Licandro, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 405 Woodlawn Rd, Long Grove, IA 52756 Phone: 832-425-7457 Fax: 563-285-5446 |